Skip to content
DataLookout
Menu

NCT04585035

Study to Evaluate D-1553 in Subjects With Solid Tumors

StatusUnknown
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 15 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
  2. Minor Study completion date: Feb 2025 to Dec 2025v16
  3. Minor Primary completion date changed from estimate of Apr 15, 2024 to Apr 30, 2024v15
  4. Notable Eligibility criteria revised
    • Study sites: 26 to 25
    v14
  5. Minor Enrollment target: estimated 200 to confirmed 180v13
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Primary completion date: Sep 29, 2023 to Apr 15, 2024
    • Interventions: D-1553 (Drug), Other (Drug) to D-1553 (Drug), D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other (Drug)
    v12
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Nov 2024 to Sep 29, 2023
    • Site details revised at 26 of 26 sites
    v11
  3. Notable Primary completion date: Nov 2022 to Nov 2024
    • Study completion date: Feb 2023 to Feb 2025
    • Site details revised at 3 of 26 sites
    v10
  4. Minor Site details revised at 2 of 26 sitesv9
  5. Minor Site details revised at 2 of 26 sitesv8
  6. Minor Collaborators expanded, about 5 wordsv6
  7. Minor Site details revised at 4 of 26 sitesv5
  8. Minor Site details revised at 9 of 26 sitesv4
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 26
    • Start date changed from estimate of Oct 2020 to Oct 2, 2020
    v3
  10. Minor Study title shortened, about 3 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Subject incidence of Dose-limiting toxicities (DLT)
Timeframe: through out the DLT period, approximately 21 days
Number of subjects participants with adverse events
Timeframe: Through study completion, approximately 3 years
Plasma concentration of D-1553 as a single agent or in combination with other therapies in subjects wiht advanced or metastatic solid tumors with KRas G12C mutation.
Timeframe: Through study completion, approximately 3 years

Arms and interventions

Dose escalation of D-1553 monotherapyExperimental

Phase 1a will evaluate up to 7 sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.

Dose combination of D-1553 with other therapiesExperimental

Phase 1b will determine the MTD of D-1553 in combination treatment in subjects with advanced or metastatic NSCLC, CRC and other solid tumors. There are multiple groups in Phase 1b for different tumor types and treatment combinations to evaluate safety, MTD and RP2D.

Phase 2 of D-1553 monotherapy and combination therapiesExperimental

The Phase 2 portion is a multi-arm, parallel, open label study to evaluate the efficacy of D- 1553 single agent and combination treatments in subjects with advanced or metastatic solid tumors with KRas G12C mutation. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose.

Drugs: D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other

Sites

25 sites in 4 countries

Australia 9, United States 7, South Korea 5, Taiwan 4